Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825858 | 0.95 | TSHR (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL1422315 | 0.89 | CA1 (0.43) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL3540841 | 0.85 | ALDH1A1 (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL2453322 | 0.84 | ALDH1A1 (0.50) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6284410 | 0.84 | ALDH1A1 (0.50) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6283344 | 0.84 | CA2 (0.53) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6279711 | 0.82 | CA2 (0.54) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL4970012 | 0.82 | KDM4E (0.48) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL1334286 | 0.82 | ALDH1A1 (0.48) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL8574884 | 0.82 | ALDH1A1 (0.48) | TSHRKDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| WO-2009144494-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| EP-2114890-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| EP-0683781-B1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | METABASIS THERAPEUTICS INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-5731432-A | Inhibitors of adenosine monophosphate deaminase | GENSIA SICOR INC. (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0683781-A4 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE. | GENSIA PHARMA (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0683781-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA PHARMACEUTICALS, INC. (US) | 1995-11-29 | — | — | EP | disclosed |
| WO-1994018200-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | TSHR 926/4885KDM4E 2943/4885USP2 3406/4885 |
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | TSHR 3585/4885KDM4E 778/4885USP2 2922/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | TSHR 487/4885KDM4E 3228/4885USP2 2717/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | TSHR 3794/4885KDM4E 1205/4885USP2 28/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | TSHR 3794/4885KDM4E 1205/4885USP2 28/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | TSHR 487/4885KDM4E 3228/4885USP2 2717/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | TSHR 485/4885KDM4E 3785/4885USP2 3499/4885 |
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | TSHR 3999/4885KDM4E 689/4885USP2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.